/
BEAM
$27.25+$0.18 (+0.66%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.8B
103M shares
52-week range
$15.60 – $38.26
51% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-79.71
Beam Therapeutics Inc. Common Stock
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
www.beamtx.com- Employees
- 522
- IPO / List date
- Feb 6, 2020
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds BEAM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 513,578 | $12.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BEAM yet.
